Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Telmisartan/Amlodipine FDC in Hypertension
NCT00618774Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telmisartan and amlodipine in hypertension (HTN), sponsored by Boehringer Ingelheim. Primary endpoints: Percentage of Participants Who Experienced Adverse Events at 52 weeks and Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate. Started Jan 2008; status: completed.
02
Drugs
telmisartanamlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00618774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00618774.